In HER2+ disease, as for other BC subtypes, a neoadjuvant strategy is usually preferred to the adjuvant one (Wuerstlein and Harbeck, 2017), except for small tumors (T < 2 cm), clinically node-negative. The gene discussed is ERBB2; the disease is breast cancer.